Efpeglenatide's superiority in signaling through the glucagon-like peptide-1 receptor (GLP-1R) and its reduced desensitization compared to other GLP-1RAs is a promising development in the field of diabetes treatment. The gene discussed is GLP1R; the disease is diabetes mellitus.